@Article{ecn.2007.0095,
AUTHOR = {Madeleine Collette, Géraldine Descamps, Catherine Pellat-Deceunynck, Régis Bataille, Martine Amiot},
TITLE = {Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells},
JOURNAL = {European Cytokine Network},
VOLUME = {18},
YEAR = {2007},
NUMBER = {3},
PAGES = {1--7},
URL = {http://www.techscience.com/ECN/v18n3/65974},
ISSN = {1952-4005},
ABSTRACT = {In multiple myeloma, a large number of growth factors (IL-6, IGF-1, FGF, HGF and HB-EGF) are
involved in promoting myeloma cell growth. In the present study, a serum-free, cytokine-free, collagen-based
assay, which does not allow the generation of spontaneous myeloma colonies, was used to identify the clonogenic
growth factors for fourteen myeloma cell lines. IL-6 is the only clonogenic factor able to stimulate both CD45+
and CD45- myeloma cell lines, generating myeloma colonies from 10 out of 14 myeloma cell lines. Using a
pharmacological Erk inhibitor, we show that the Erk/MAPK pathway is involved in IL-6-induced clonogenicity
of CD45+, but not CD45- myeloma cell lines. In contrast to IL-6, the other growth factors (IGF-1, FGF, HGF and
HB-EGF) stimulate only some myeloma cell lines, but always CD45-, and less effectively than IL-6. Among them,
IGF-1 is the most potent, generating myeloma colonies from five out of eight CD45- myeloma cell lines. Finally,
the capacity of IGF-1 and FGF to stimulate the clonogenicity of CD45- myeloma cells correlates with their ability
to stimulate the Erk/MAPK pathway. We conclude that CD45 expression plays a crucial role in determining
signaling and proliferation of human myeloma cell responses to IL-6, IGF-1 and other growth factors. The poor
outcome of CD45- myeloma patients could be related to the capacity of CD45-myeloma cells to take advantage of
multiple growth factors.},
DOI = {10.1684/ecn.2007.0095}
}